



#10/B  
4-3-02  
NW

PATENT

Attorney Docket 044508-5001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Gerald Quinnan et al.** )  
Application No. **09/762,261** )  
Filed: **May 29, 2001** )  
For: **Expression and Characterization of HIV-1** )  
    **Envelope Protein Associated With a Broadly** )  
    **Reactive Neutralizing Antibody Response** )

Group Art Unit: 1648

Examiner: **Shanon Foley**

RECEIVED  
APR 02 2002  
TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT & AMENDMENT UNDER 37 C.F.R. 1.115**

In response to the Restriction Requirement dated January 30, 2002 (Paper No. 7), the period for response having been extended from February 28, 2002 to March 30, 2002 by payment of a one-month extension of time, please amend the above-referenced application as follows:

**In the Claims:**

Please cancel claim 1 without prejudice or disclaimer of Applicants' right to file divisional applications containing the subject matter of this claim and amend claims 5-9, 12, 16-17 and 19-20 as follows:

**Please amend claim 5-9, 12, 16-17 & 19-20 as follows:**

5. (Once Amended) A vaccine composition comprising an isolated HIV-1 envelope protein or fragment thereof of any one of claims 2-4 and a pharmaceutically acceptable carrier.

6. (Once Amended) An immunogenic composition comprising an isolated HIV-1 envelope protein or fragment thereof of any one of claims 2-4 and a pharmaceutically acceptable carrier.

7. (Once Amended) An isolated nucleic acid molecule encoding the HIV-1 envelope protein or fragment thereof of any one of claims 2-4.

8. (Once Amended) A fusion protein comprising all or a portion of a microbiological antigen into which any one of the proteins of claims 2-4 has been inserted.

b1